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Introduction
Cervical cancer is ranked the fourth most common 
cancer among females and the eighth most common 
cancer gobally according to the World Health Organization 
and International Agency for Cancer Research (IARC) 
(GLOBOCAN, 2018). High risk human papillomavirus 
(HPV) including HPV 16 and 18 are the main etiological 
agents involved in cervical cancer development (Zur 
Hausen, 2002). The viral oncoproteins E6 and E7 interact 
and degrade p53 and RB tumour suppressor genes in the 
host cells. This causes increased cell proliferation and 
reduction in apoptosis, leading to immortalization of cells 
and development of cancer (Zur Hausen, 2002). 
The family of minichromosome maintenance complex 
(MCM) proteins (MCM2–7 and MCM10) are essential for 
initiating the process of DNA replication and cell division 
(Bell and Dutta, 2002; Bochman and Schwacha, 2009). 
The MCMs act as replicative helicases, and together with 
CDC6 and CDT1, are components of the pre-replicative 
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complex (Bell and Dutta, 2002; Bochman and Schwacha, 
2009). Additional factors, such as cyclin-dependent 
kinase (CDK) and polymerase are recruited to activate 
DNA unwinding and initiate DNA replication during S 
phase.  Throughout late S, G2 and early M phases, CDKs 
cause dissolution of these components, thereby making 
DNA replication a ‘once per cycle’ affair. MCMs are 
markers for proliferation, evidenced by high activity in 
proliferating cells, and down-regulation in quiescence or 
in cells undergoing differentiation (Freeman et al., 1999; 
Madine et al., 2000). Abnormalities in its function could 
result in chromosomal defects that may contribute to 
tumorigenesis. 
The MCM family members have a DNA-dependent 
ATPase motif in the central domain. MCM4, 6, and 7 form 
a hexameric complex and function as a DNA helicase in 
vitro (Tanaka et al., 1997). This suggests that MCM4, 6 
and 7 complex acts as a DNA-unwinding enzyme during 
replication. In contrast, MCM2, 3, and 5 proteins were 
found to inhibit the helicase activity of MCM 4, 6, and 7 
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by disassembling this hexamer (Sato et al., 2000). In vivo 
findings indicate that MCM2-7 proteins act as a replicative 
helicase that is responsible for fork movement (Labib et 
al., 2000). Therefore, MCM2-7 complex is likely to be 
involved in DNA replication as a helicase. 
MCMs are candidate markers for cell proliferation 
and increased levels of MCMs indicate proliferation of 
malignant cells. Moreover, some evidence suggests that 
MCMs predict tumour progression. Studies have indicated 
that MCM proteins are highly expressed in several types 
of cancers, such as lung, breast, colon, and other cancers 
(Shetty et al., 2005; Giaginis et al., 2009; Liu et al., 
2017). They may also be useful as potential diagnostic or 
prognostic markers (Giaginis et al., 2010). 
MCM2 has been recognised as a useful marker in 
screening for cervical carcinoma (Amaro Filho et al., 
2014) oral squamous cell carcinoma (Razavi et al., 
2015) and medulloblastoma (Jin et al., 2014). MCM3 
was identified as a better indicator for the evaluation of 
dysplastic oral lesions compared to Ki-67  (Lameira et 
al., 2014). In addition, mutation of MCM4 was detected 
in skin cancer cells, that affects the DNA helicase 
activity of the MCM2-7 complex (Ishimi and Irie, 2015). 
Furthermore, MCM5 was associated with breast cancer 
prognosis (Eissa et al., 2015), while MCM7 may be 
useful in predicting the prognosis of papillary urothelial 
neoplasia (Guan et al., 2015). 
HPV infection is normally cleared by the immune 
system but if an infection persists in the cervical 
epithelium, the host and viral genomes undergo alterations 
that cause cervical cells to transform into a distinctive pre-
cancerous stage termed squamous intraepithelial lesion 
(SIL), and further into invasive squamous cell carcinoma 
(SCC). The main reason for the persistence of infection 
is due to expression of HPV E6 and E7 proteins in host 
cells which cause increased levels of cell cycle proteins 
such as p16, Ki-67 and MCM (Pett and Coleman, 2007; 
Doorbar et al., 2015; Graham, 2017). p16 is considered a 
key tissue biomarker in determining the increased HPV 
E6 and E7 activity in pre-cancerous lesions and cancer of 
the cervix (Reuschenbach et al., 2014). MCM, a cellular 
marker of DNA replication, has also been established as an 
alternative biomarker (Griffin et al., 2015). Carcinogenesis 
is inextricably linked with loss of cell cycle regulation 
and abnormal DNA replication. Several studies showed 
increased MCM2 protein expression in HPV-infected 
cells (Amaro Filho et al., 2014; Zheng, 2015) and cervical 
cancer (Das et al., 2013; Amaro Filho et al., 2014). Very 
few studies have focused on pre-cancerous lesions, with 
variable results (Nicol et al., 2012; Saritha et al., 2018). 
Therefore, this study provides a unique advantage 
to study the expression of MCM through the process of 
cervical carcinogenesis. This study aimed to evaluate 
MCM2, 4, 5 and 7 genes expression profiles and their 
putative role in HPV-associated cervical carcinogenesis. 
Further assessment of MCM2 protein was performed to 
investigate it’s potential as a marker in detecting pre-
cancerous lesions and cervical cancer. 
Materials and Methods
Tissue samples
Histologically confirmed cases of normal cervix, 
low-grade squamous intraepithelial neoplasia (LSIL), 
high-grade squamous intraepithelial neoplasia (HSIL) and 
squamous cell carcinoma (SCC) were selected from the 
hospital pathology records. Patients’ demographic data 
remained confidential and only the pathology report was 
acquired. The formalin-fixed paraffin-embedded (FFPE) 
cervical tissue samples comprised biopsies, conization 
and hysterectomy specimens. The LSIL, HSIL and SCC 
samples were pre-determined to be HPV type 16 and/or 18 
status by immunohistochemistry and real time PCR. Only 
HPV 16/18 positive cases of SIL and SCC were included 
in the study. Normal cervical tissues were obtained from 
hysterectomy specimens removed for other non-cervical 
related conditions. They were confirmed HPV negative 
and served as negative control. The pathology diagnoses 
were reviewed by a pathologist (Gurjeet Kaur). Each 
histological group comprised of three cases. Approval 
was obtained from the Human Research Ethics Committee 
of Universiti Sains Malaysia (USM/JEPeM/279.3 (1)). 
RNA extraction  
Gene expression studies were performed on twelve 
samples; 3 normal cervix, 3 each of HPV 16/18-positive 
LSIL, HSIL and SCC. Laser capture microdissection was 
used to isolate the pathological lesion from the tissue 
sections. RNA extraction was done on the micro dissected 
tissues using RNeasy FFPE extraction kit (Qiagen, 
Germany) according to the manufacturer’s protocol. The 
purity of the RNA was measured using Nanodrop and 
quantified using a bioanalyser (Agilent, USA). 
Human Transcriptome Array 2.0
GeneChip Human Transcriptome Array 2.0 (HTA 2.0) 
Affymetrix, USA was used to profile the gene signatures 
involved in the disease progression of cervical cancer. 
This study focused on the expression profile of MCM 
family genes, comprising MCM2, 4, 5 and 7. Sensation 
plus FFPE WT kit (Affymetrix, USA) was used for all 
12 samples following the manufacturer’s protocol. Upon 
hybridization, the chip was scanned using Affymetrix 
GeneChip Scanner 3000. The data was analysed by 
Affymetrix GeneChip Operating Software (GCOS), which 
contains qualitative and quantitative analysis for every 
probe set. Affymetrix® Transcriptome Analysis Console 
(TAC) software was used to determine the expression 
profile of MCM genes family in each histological group 
compared to normal cervix. 
 
nCounter® PanCancer Pathway Array
To validate the differentially expressed MCM2, 
4, 5 and 7 genes, nCounter® PanCancer Pathway 
Array (NanoString, USA) was used according to the 
manufacturer’s protocol for mRNA expression profiling, 
comparing the gene expression in each histological group 
to normal cervix. The data was analysed with nSolver 3.0 
software (NanoString, USA). 
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room temperature for 1 hour. Primary rabbit monoclonal 
anti-MCM2 antibody (Abcam, UK, 1:50 dilution) was 
applied and incubated overnight at 4oC. Biotinylated 
secondary antibody, goat anti-rabbit, (Abcam, UK), 1:500 
was added, followed by avidin-biotin complex, Vectastain 
ABC reagent (Vector Laboratories, USA) for one hour 
each. Slides were rinsed thrice with TBS-T between the 
incubation steps. Finally, DAB (3.3′-diaminobenzidin) 
chromogen (Dako, USA) was added and allowed to 
develop for 10 mins, rinsed and counterstained with 
Mayer’s haematoxylin (Dako, USA). Under light 
microscope, brown staining cervical epithelium nuclei 
signified positive protein expression. The TMA slides 
were scanned using a Hamamatsu, NanoZoomer S60 
Digital Slide Scanner. The histoscore was calculated by 
multiplying the percentage of positivity score and staining 
intensity score, shown in Table 1. 
Statistical Analysis
The association between MCM2 protein expression 
and histological groups were analysed using chi-square 
test, with statistical significance set at p <0.05, using IBM 
SPSS V24.0 software package for Windows. 
Results
Human Transcriptome Array 2.0 was performed 
to determine the MCM2, 4, 5 and 7 genes expression 
profiles in twelve FFPE samples of normal cervix, 
Evaluation of immunohistochemical expression of MCM2 
protein in tissue microarrays 
Two FFPE tissue microarrays (TMA) (BB10011 and 
CR1003, Biomax USA) were used for MCM2 protein 
evaluation containing 10 cases of normal cervix, 10 
LSIL, 10 HSIL and 43 SCC cases, with two identical 
tissue cores per case. HeLa cell block was used as the 
positive control. Briefly, HeLa cells were washed with 
phosphate-buffered saline and centrifuged at high speed 
to remove the supernatant. After fixation of the cell pellet 
in 4% formaldehyde for 24 hours at 4oC, the sample was 
centrifuged at 1800 RPM for 10 minutes. Then the pellet 
was incubated in 70% ethanol for 30 minutes at room 
temperature, followed by centrifugation at 1800 RPM for 
10 minutes. The supernatant was removed. The cells were 
incubated overnight in 100% ethanol at 4oC. Following 
that, the fixed cells were centrifuged at 1,800 RPM to 
remove the supernatant. The cell pellet was folded in lens 
paper and placed in a cassette for routine tissue processing, 
paraffin embedding and sectioning. 
The TMAs and positive control tissue were subjected 
to immunohistochemical staining using a standard 
protocol.  Briefly, antigen retrieval was performed with 
citrate buffer (10mM, pH 6.0) and heated in a microwave 
oven for 20 mins at low setting. After treatment with 
peroxidase-blocking solution (Dako, USA), sections 
were blocked with 5% bovine serum albumin (Sigma-
Aldrich, USA) and 5% goat serum (Biowest, France) 
in Tris-buffered saline-Tween-20 (TBS-T) solution at 
Figure 1. Gene Expression Profile of MCM Gene Family in Histological Groups of Low-Grade Squamous 
Intraepithelial Lesion (LSIL), High-Grade Squamous Intraepithelial Lesion (HSIL) and Squamous Cell Carcinoma 
(SCC), each Group Compared to Normal Cervix. Results were obtained from (a) HTA and (b) NanoString pan-cancer 
pathway. Bars represent the fold change difference in each histological group compared to normal cervix. 
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HPV-associated LSIL, HSIL and SCC. The results were 
validated using the NanoString platform. Following that, 
immunohistochemical expression of MCM2 protein was 
evaluated in 73 cases of cervical  lesions contained in two 
tissue microarrays. 
Gene expression profiling using Human Transcriptome 
Array (HTA 2.0) and NanoString 
MCM genes expressions were determined in LSIL, 
HSIL and SCC groups, compared to normal cervix, using 
Human Transcriptome Array (HTA2.0) and validated 
by NanoString nCounter® PanCancer Pathway Array. 
In general, there was increase in fold change of MCM2, 
4, 5 and 7 genes during the progression from LSIL 
to HSIL with the highest fold change in SCC (Figure 
1). NanoString data showed concordance in trends of 
expression except for LSIL whereby  MCM5 gene was 
downregulated in HTA but upregulated in NanoString. 
In NanoString analysis, MCM2, 4, and 7 genes were 
upregulated in HSIL and SCC. MCM2 gene had the 
highest fold change in SCC compared to normal cervix.
MCM2 immunohistochemical expression 
Histoscore was assessed on 42 cases of SCC, 10 LSIL, 
10 HSIL and 9 normal cervix in the TMAs. One tissue 
core of SCC and normal cervix did not contain squamous 
epithelium, hence excluded from the study. MCM2 
protein was expressed in nuclei of cervical epithelial 
cells and HeLa cells. Stromal inflammatory cells showed 
both nuclear and cytoplasmic staining. In normal cervix, 
nuclear staining was observed in basal and parabasal 
cells, whereas in SIL, dysplastic cells occupying varying 
degrees of epithelial thickness were positively stained. 
The photomicrograph images of MCM2 histoscore 
expressions are shown in Figure 2.
The histoscore results of MCM2 protein expression 
are depicted in Table 2. Overall, MCM2 expression was 
positive in 54 (76.1%) of 71 cases. The highest expression 
was noted in HSIL group. Chi-square test demonstrated 
that there was a significant difference in MCM2 expression 
Table 1. Histoscore Method for Immunohistochemical 
Expression
Percentage of positivity Score Staining intensity Score
< 1% positive cells 0 No staining 0
1% - 25% positive cells 1 Weak staining 1
26% - 50% positive cells 2 Moderate staining 2
51% - 75% positive cells 3 Strong staining 3
≥ 75% positive cells 4
Final histoscore, Percent positivity score x Staining intensity score; 
Score : 0, Negative; 1 – 3/12, Low expression; ≥ 4/12, High expression
Histological MCM2 histoscore Total Histological group vs normal 
group Negative n (%) Low n (%) High n (%) n (%) p value p value
Normal 3 (33.3) 4 (44.4) 2 (22.2) 9 (100)
LSIL 1 (10.0) 3 (30.0) 6 (60.0) 10 (100) 0.212
HSIL 0 (0.0) 1 (10.0) 9 (90.0) 10 (100) 0.039 0.01
SCC 13 (31.0) 14 (33.3) 15 (35.7) 42 (100) 0.713
Total 17 (23.9) 22 (31.0) 32 (45.1) 71 (100)
Chi-square test, statistical significance set at p value <0.05; LSIL, low-grade squamous intraepithelial lesion; HSIL high-grade squamous 
intraepithelial lesion; SCC, squamous cell carcinoma.
Table 2. MCM2 Histoscore in Normal Cervix, LSIL, HSIL and SCC, and Comparison between Individual Histological 
Groups and Normal Cervix
Figure 2. Digital Scanned Images of MCM2 Immunohistochemical Staining Showing Brown Nuclear Staining in 
Cervical Epithelial Cells. (A) squamous cell carcinoma (SCC) showing high histoscore, (B) high-grade squamous 
intraepithelial lesion (HSIL) with high histoscore, (C) Normal cervix with low histoscore, positive staining in basal 
cells (arrows), (D) squamous cell carcinoma (SCC) with negative expression (objective x 20).
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between the histological groups (P = 0.039), and between 
HSIL and normal cervix (P = 0.010). 
Discussion
During cervical neoplastic transformation, cells 
acquire the ability to sustain proliferation and resist cell 
death or apoptosis. The HPV viral oncoproteins, primarily 
the E6 and E7, dysregulate the normal function of host’s 
tumour suppressor genes p53 and pRb, causing the cells 
to enter the S phase and continue proliferation. This 
event eventually leads to abnormalities in cell growth 
and function. Progression through the cell cycle requires 
expression of genes that regulate the cell cycle check 
points (G1 and G2). Up-regulation of CDKN2A, also 
known as p16, in the early stage of cervical cancer is an 
indication of the host response in inactivating pRb gene 
and releasing the E2F family (Gius et al., 2007). The 
interaction between high risk HPV types 16/18 and p16 
appears to play a major role in cervical carcinogenesis. 
DNA replication is a key process in cell proliferation 
and cell growth. The abnormal proliferation of tumour 
cells is characterized by irregularities in pathways 
involved in DNA replication, cell cycle, and apoptosis. 
A series of events that occurs during HPV infection 
causes the host cells to undergo unscheduled cell cycle. 
This phenomena leads to uncontrolled cell division 
and enhanced cell proliferation, further causing cancer 
development. In HPV-associated cervical cancer, the 
cancer cells upregulate specific genes that control several 
steps in DNA replication (Cheng et al., 2017). MCMs have 
been identified as the key regulators in DNA replication, 
involved in the helicase activity for fork movement.
The MCM  proteins are markers of cell proliferation 
and have been shown to be highly expressed in a variety of 
cancers including breast, lung, colorectal and many other 
types of cancers (Shetty et al., 2005; Giaginis et al., 2009; 
Liu et al., 2017). Though studies have reported on MCM 
expression in cervical cancer, very few have analysed 
the whole spectrum of transformation of HPV-infected 
cervix into pre-cancerous lesions (LSIL and HSIL) 
and further into invasive cancer (Das et al., 2013; Niu 
et al., 2017; Li et al., 2018; Saritha et al., 2018). This 
study aimed to evaluate the MCM mRNA expressions in 
HPV-associated pre-cancerous and cervical cancer tissues, 
to better understand their role in cervical carcinogenesis. 
Moreover, the protein expression of MCM2 was also 
determined in this study. 
Our results on transcriptomic profiling using both 
Human Transcriptome Array (HTA) and NanoString 
clearly demonstrated an upregulation and increasing fold 
change of MCM2, 4, 5 and 7 genes during the progression 
from LSIL to HSIL and SCC, compared to normal cervix. 
The highest fold change was in the SCC group. The results 
in our study concur with others that report an upregulation 
of MCM2, 4 and 5 genes in cervical SCC compared to 
normal samples (Niu et al., 2017; Li et al., 2018). MCM2, 
4, 5,6 and 7 were also found to be upregulated in cervical 
cancer using semi-quantitative RT-PCR technique (Das 
et al., 2013). Pre-cancerous lesions were not in the scope 
of these studies. In LSIL, dysplastic cells are limited to 
the lower one third of cervical epithelium, reflecting a 
low number of cells in the proliferative phase. It is also 
well recognised that a high percentage of LSIL cases can 
revert to normal when HPV infection is cleared by host 
immunological mechanisms (Hausen, 2002). Therefore, 
the genomic signature of LSIL would understandably 
be quite similar to normal cervix, demonstrated by 
approximately one-fold change in the MCM genes. In 
HSIL, the MCM gene family expression is upregulated as 
the abnormal dysplastic cells acquire genetic alterations 
that promote cell growth and survival. As the disease 
progresses into cancer, there is uncontrolled cell division 
and DNA replication, reflected by a further increase in 
MCM gene expression. 
Interestingly, MCM2 showed the highest upregulation 
in SCC compared to normal cervix, from the NanoString 
data. When comparing both methods of transcriptomic 
profiling, it was evident that HTA showed a lower gene 
expression fold change compared to NanoString. This 
is related to the distinct types of expression detection 
systems that give superiority to NanoString (Geiss 
et al., 2008; Tsang et al., 2017). In NanoString, the 
direct measurement of mRNA expression levels using 
multiplexed, colour-coded probe pairs without the need 
for amplification  is considered more sensitive than 
microarrays and similar in sensitivity to real-time PCR 
(Geiss et al., 2008).  Studies have reported that results from 
NanoString are concordant to the HTA platform (Zhu et al., 
2016; Delmonico et al., 2019). Furthermore, NanoString 
is found to be suitable for accurately measuring mRNA 
transcripts in archival FFPE-derived biological samples, 
which are acknowledged to have poor quality and low 
yield of RNA (Reis et al., 2011; Tsang et al., 2017). 
Upregulation of MCM2 at mRNA levels prompted us to 
focus on the expression of MCM2 at protein level and 
to identify it’s potential as a biomarker in screening for 
cervical carcinoma, as previously reported by Amaro 
Filho et al., (2014).
Histologically, MCM2 expression was restricted to 
the nuclei of basal and parabasal layers of normal cervix 
squamous epithelial cells in the tissue microarrays. 
Whereas in SIL and SCC, the nuclei of dysplastic and 
cancer cells respectively were prominently stained. A 
similar staining pattern was reported by Nicol et al., 
(2012), suggesting that dysregulation of cell-cycle 
entry in cervical carcinogenesis was prominent in the 
epithelial cells (Freeman et al., 1999). There was a 
significant difference in MCM2 histoscore between the 
three histological groups, with the highest histoscore 
noted in HSIL compared to normal (P = 0.010). MCM2 
was ubiquitously expressed across all histological groups 
reflected by positive staining in 6 of 9 (66%) cases of 
normal cervix, 29/42 (69%) in SCC, 9/10 (90%) in LSIL 
and 10/10 (100%) in HSIL in the tissue microarrays. 
Previous studies reported an increasing MCM2 expression 
pattern from normal cervix to SIL and the highest in SCC 
(Nicol et al., 2012; Zheng, 2015; Saritha et al., 2018). 
MCM2, 3 and 4 were also observed to be highly expressed 
in cancer cells compared to normal cervical epithelial cells 
(Ishimi et al., 2003; Amaro Filho et al., 2014).  
There are several plausible reasons for this discrepancy. 
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Firstly, in our study, MCM2 protein expression did not 
correlate with its gene expression. MCM2 gene was found 
to be highly upregulated in SCC group though the MCM2 
protein was only highly expressed in 30% of SCC cases in 
the tissue microarrays. Notwithstanding the low numbers 
of normal cervix and SIL cases in the current study, it is 
known that gene expression and protein expression could 
be inversely linked as post-transcriptional modifications 
are key to the final synthesis of the protein. MCM2 protein 
processing including its half-life and degradation in cells 
may also account for the differences observed above. The 
MCM2 protein has been shown to function as a hexamer 
complex, indicating that the formation of this complex is 
required to ensure its activation state (Sun et al., 2014), 
and this was not found at the gene level. High MCM2 
expression has been correlated with high-risk HPV and 
p16/CDKN2A expression in cervical cancer samples 
(Santin et al., 2005; Akagi et al., 2014; Zheng, 2015; Liao 
et al., 2018). 
The upregulated gene expression of MCM2 in 
the current study may be due to the presence of HPV 
oncoproteins in the samples. In the natural viral life 
cycle of high-risk HPV infection of the cervix, the HPV 
E7 oncoprotein causes the inactivation of RB tumor 
suppressor gene in the host cells. Degradation of RB 
activates the CDKs to trigger E2F transcription factor 
leading to activation of cell proliferation pathway, which 
is partly regulated by the MCM genes involved in initiating 
DNA replication and cell division. This is proven in 
a study using HeLa cells, where HPV E7 oncoprotein 
binds to hyperphosphorylated RB to destabilize the RB/
E2F complex (Goodwin and DiMaio, 2000). Therefore, 
the HPV oncoprotein indirectly causes upregulation of 
MCM genes and proteins. Studies on gene profiling have 
demonstrated upregulation of MCM genes as part of the 
DNA replication pathway in HSIL and invasive cervical 
cancer (Santin et al., 2005; Niu et al., 2017). Initially as 
a response to HPV infection, basal cervical epithelial 
cells are postulated to induce genes that allow the virus 
to replicate by evading the host cellular immune system 
and favour cell proliferation which ultimately transforms 
infected cells into LSIL (Gius et al., 2007). 
The results reaffirm MCMs as essential in DNA 
replication and markers of cell proliferation. The 
diagnostic value of MCM2 has been examined by various 
studies. Due to its ubiquitous nature, MCM2 is less likely 
to be considered on its own as a sensitive diagnostic 
marker for cervical cancer but shows a certain degree of 
promise as a concatenated detection method along with 
HPV typing, p16 or Ki-67 biomarkers (Zheng, 2015; Liao 
et al., 2018). 
In conclusion, the upregulation of MCM genes 
expression in cervical carcinogenesis reaffirms MCM 
as a proliferative marker, whereby dysplastic and cancer 
cells proliferation become increasingly dysregulated 
and uncontrolled. The strong MCM2 protein expression 
in HSIL may be helpful as an added screening tool in 
detecting pre-cancerous cervical lesions.  
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